Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?-Reference-Cited by-同舟云学术

Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Published:2020-10-17 Issue:3 Volume:185 Page:657-666
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Garcia-Tejedor Amparo^ORCID,Fernandez-Gonzalez Sergi,Ortega Raul,Gil-Gil Miguel,Perez-Montero Hector,Fernandez-Montolí Eulalia,Stradella Agostina,Recalde Sabela,Soler Teresa,Petit Anna,Bajen Maria Teresa,Benitez Ana,Guma Anna,Campos Miriam,Pla Maria J.,Martinez Evelyn,Laplana Maria,Pernas Sonia,Perez-Sildekova Diana,Catala Isabel,Ponce Jordi,Falo Catalina

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05970-2.pdf

Reference47 articles.

1. Cavanaugh KM (2011) Effects of early exercise on the development of lymphedema in patients with breast cancer treated with axillary lymph node dissection. J Oncol Pract 7(2):89–93

2. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ et al (2016) Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072–1078

3. Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Köbrunner SH et al (2006) In: Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy. Cancer 107(2):242–250. http://www.ncbi.nlm.nih.gov/pubmed/16770785. Accessed 2 Oct 2014

4. Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546–553

5. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. https://doi.org/10.1016/S1470-2045(10)70207-2

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer;The American Journal of Surgery;2024-10

2. Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy;American Society of Clinical Oncology Educational Book;2024-06

3. Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study;Breast Cancer Research;2024-04-17

4. Prognostic Importance of Axillary Lymph Node Response to Neoadjuvant Systemic Therapy on Axillary Surgery in Breast Cancer—A Single Center Experience;Cancers;2024-03-27

5. Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?;The Breast;2024-02